Lidomide (Lenalidomide) 25mg 30’ct capsules
Lidomide 25 (Lenalidomide) is a medication primarily used for the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Each capsule contains 25 mg of lenalidomide.Key points about Lidomide 25 mg capsules:
- Lenalidomide is structurally related to thalidomide, a known human teratogenic substance that causes severe birth defects. Lenalidomide can also cause serious birth defects or death to a developing baby.
- Lidomide 25 mg capsules are white opaque cap and white opaque body, size ‘0’ hard gelatin capsules imprinted with ‘H’ on cap and ‘L7’ on body, filled with off white to pale yellow color powder.
- The recommended dosage varies based on the indication and patient’s kidney function. For multiple myeloma, the typical dose is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
- Lidomide 25 mg capsules should be stored at 20°C to 25°C (68°F to 77°F). Care should be exercised in handling the capsules, as they should not be opened or broken.
- Lidomide 25 mg capsules are available in bottles of 21 and 100 capsules
>IMPORTENT NOTE… Those customers who belongs to lahore avail the opportunity of cash on delivery(COD) with in 30mints.
> ALL ALTERNATIVES BRANDS ARE AVAILABLE
>ORIGNAL & IMPORTED
> For maore details & price kindly contact on whatsapp.
Description
Lidomide 25 (Lenalidomide) is a medication primarily used for the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Each capsule contains 25 mg of lenalidomide.Key points about Lidomide 25 mg capsules:
- Lenalidomide is structurally related to thalidomide, a known human teratogenic substance that causes severe birth defects. Lenalidomide can also cause serious birth defects or death to a developing baby.
- Lidomide 25 mg capsules are white opaque cap and white opaque body, size ‘0’ hard gelatin capsules imprinted with ‘H’ on cap and ‘L7’ on body, filled with off white to pale yellow color powder.
- The recommended dosage varies based on the indication and patient’s kidney function. For multiple myeloma, the typical dose is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
- Lidomide 25 mg capsules should be stored at 20°C to 25°C (68°F to 77°F). Care should be exercised in handling the capsules, as they should not be opened or broken.
- Lidomide 25 mg capsules are available in bottles of 21 and 100 capsules
Indications
Lidomide 25 mg capsules are indicated for the treatment of:
- Multiple myeloma
- Myelodysplastic syndromes
- Mantle cell lymphoma
Dosage
The recommended dosage is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles, often in combination with other medications like dexamethasone.
Storage
The capsules should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F).
Appearance
Each capsule contains 25 mg of lenalidomide and is filled with white to off-white powder. The capsule shell is white opaque with a black imprint of “1035” and a light blue opaque body.
Safety
Lidomide 25 mg capsules are known to cause serious side effects, including birth defects. Females who are pregnant or planning to become pregnant should not take these capsules.
Key Benefits of Lidomide 25 mg (Lenalidomide) Capsules
Based on the search results, the key benefits of Lidomide 25 mg (Lenalidomide) capsules include:Indications
- Treatment of multiple myeloma, a type of cancer affecting plasma cells in the bone marrow
- Treatment of myelodysplastic syndromes, a group of disorders where the bone marrow fails to produce enough healthy blood cells
- Treatment of mantle cell lymphoma, a rare type of non-Hodgkin lymphoma
Dosage
- Recommended dosage is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles
- Can be used in combination with other medications like dexamethasone
Safety
- Lenalidomide is structurally related to thalidomide, which is known to cause severe birth defects
- Careful monitoring and dose adjustments are required to manage potential side effects like thrombocytopenia and neutropenia
Key Ingredients
The key ingredient in Lidomide 25 mg capsules is:
- Lenalidomide – 25 mg per capsule
The capsules also contain the following excipients:
- Lactose – 200 mg per capsule
- Other inactive ingredients like the capsule shell material
Mechanism of Action of Lidomide 25 mg (Lenalidomide) Capsules
The exact mechanism of action of lenalidomide, the active ingredient in Lidomide 25 mg capsules, is not fully characterized. However, the available evidence suggests the following:Anti-Neoplastic Effects
- Lenalidomide has been shown to inhibit the proliferation of certain cancer cell lines, including multiple myeloma cells.
- It appears to induce cell cycle arrest and apoptosis (programmed cell death) in multiple myeloma cells.
Immunomodulatory Effects
- Lenalidomide can modulate the immune system by inhibiting the secretion of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells.
Anti-Angiogenic Effects
- Lenalidomide has been found to inhibit the expression of cyclooxygenase-2 (COX-2), an enzyme involved in angiogenesis (the formation of new blood vessels).
The combination of anti-neoplastic, immunomodulatory, and anti-angiogenic properties is thought to contribute to the therapeutic effects of lenalidomide in the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. However, the full mechanism of action is still under investigation.
LenalidomideMedication used to treat multiple myeloma and other disordersMoreUsesTreats multiple myeloma, smoldering myeloma, and myelodysplastic syndromesCommon Side EffectsDiarrhea, itchiness, joint pain, fever, headaches, and sleep disturbancesSevere Side EffectsLow blood platelets, low white blood cells, and blood clotsThe chemical structure of lenalidomide, the active ingredient in Lidomide 25 mg capsules, is:Lenalidomide chemical structureKey features of the lenalidomide structure:
- It is a 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione derivative.
- The molecular formula is C13H13N3O3 and the molecular weight is 259.26 g/mol.
- It contains an isoindolinone ring system with an amino group at position 4 and a 2,6-dioxopiperidine ring.
- The systematic name is 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione.
Lenalidomide is structurally related to thalidomide, with modifications made to improve its potency and reduce its toxicity. The structural similarities between lenalidomide and thalidomide contribute to their shared immunomodulatory, antiangiogenic, and antineoplastic properties.
Reviews
There are no reviews yet.